JJ Bienaimé, BioMarin CEO
BioMarin buffs up data on hemophilia A gene therapy as FDA decision deadline approaches
BioMarin says its Phase III study for a hemophilia A gene therapy met its primary and secondary endpoints at year three, and it has added …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
